

ABBOTT LABORATORIES  
Form 8-K  
September 19, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

September 14, 2007  
Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in its charter)

---

**Illinois**  
(State or other Jurisdiction of Incorporation)

**1-2189**  
(Commission File Number)

**36-0698440**  
(I.R.S. Employer Identification No.)

---

**100 Abbott Park Road**  
**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices) (Zip Code)

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Registrant's telephone number, including area code: (847) 937-6100

**Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

On September 14, 2007, Abbott Laboratories Board of Directors amended the first sentence of Article III, Section 2 of Abbott's bylaws to provide that Abbott's Board of Directors shall consist of twelve persons, effective October 1, 2007. Previously, it provided that the Board of Directors consisted of thirteen persons.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Exhibit No.	Exhibit
-------------	---------

3.1	By-Laws of Abbott Laboratories, as amended and restated as of October 1, 2007
-----	---

---

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Abbott Laboratories**

Date: September 18, 2007

By: /s/ Thomas C. Freyman  
Thomas C. Freyman  
Executive Vice President,  
Finance and Chief Financial Officer

-

-



**Exhibit Index**

**Exhibit**

**No.            Exhibit**

3.1            By-Laws of Abbott Laboratories, as amended and restated as of October 1, 2007

---